Amsterdame \u012fsik\u016brusi biotechnologij\u0173 bendrov\u0117 \u201eVectorY Therapeutics\u201c pritrauk\u0117 74,5 mln. eur\u0173 naujo finansavimo, skirto kurti gydymo sprendimus nuo amiotrofin\u0117s lateralin\u0117s skleroz\u0117s (ALS) ir kit\u0173 neurodegeneracini\u0173 lig\u0173.<\/p>\n
Apie sandor\u012f prane\u0161ta portale \u201eEU-Startups\u201c \u2013 nurodoma, kad prie investuotoj\u0173 prisijung\u0117 ir nauji partneriai, tarp j\u0173 \u201eAngelini Ventures\u201c, Nyderland\u0173 pl\u0117tros finans\u0173 institucija \u201eInvest-NL\u201c bei Europos investicij\u0173 bankas (EIB).<\/p>\n
Finansavime dalyvavo ir anks\u010diau \u012f bendrov\u0119 investav\u0119 rinkos dalyviai, \u012fskaitant \u201eForbion\u201c, \u201eEQT Life Sciences\u201c, \u201eMRL Ventures\u201c, \u201eInsight Partners\u201c, BGV, \u201eEli Lilly and Company\u201c bei ALS Investment Fund.<\/p>\n
\u201eVectorY Therapeutics\u201c \u012fkurta 2020 metais ir veikia Amsterdamo \u201eScience Park Matrix Innovation Centre\u201c. Bendrov\u0117 kuria precizi\u0161kai \u012f taikinius nukreiptas terapijas, kurios, jos teigimu, gal\u0117t\u0173 sustabdyti ir potencialiai pakeisti neurodegeneracini\u0173 lig\u0173 progresavim\u0105.<\/p>\n
\u012emon\u0117 kuria vadinam\u0105sias vektorizuotas antik\u016bn\u0173 terapijas: gydomieji antik\u016bnai derinami su vienkartiniu adenoasocijuoto viruso (AAV) pagrindu veikian\u010diu pristatymu tiesiai \u012f centrin\u0119 nerv\u0173 sistem\u0105.<\/p>\n
Bendrov\u0117 teigia, kad toks metodas gali pad\u0117ti spr\u0119sti \u012fprastini\u0173 terapij\u0173 problemas \u2013 vaisto pristatym\u0105 \u012f reikiamas vietas, poveikio trukm\u0119 ir geb\u0117jim\u0105 pasiekti biologinius taikinius smegenyse bei nerv\u0173 sistemoje.<\/p>\n
\u201eForbion\u201c partneris Wouteris Joustra pabr\u0117\u017e\u0117, kad \u012fmon\u0117s darbas su pagrindine programa VTx-002, \u012fskaitant PIONEER-ALS tyrimo pl\u0117tr\u0105, yra svarbus \u017eingsnis vertinant \u0161ios krypties potencial\u0105.<\/p>\n
\u201eVectorY Therapeutics\u201c nurodo turinti keturi\u0173 program\u0173 portfel\u012f: VTx-002 nukreipta \u012f TDP-43 baltymo agregacij\u0105 ALS atveju, VTx-003 \u2013 \u012f mutavus\u012f HTT baltym\u0105 Huntingtono ligos kontekste, VTx-004 \u2013 \u012f TDP-43 frontotemporalin\u0117s demencijos (FTD) atveju, o VTx-005 \u2013 \u012f fosforilint\u0105 tau baltym\u0105 Alzheimerio ligai.<\/p>\n
Bendrov\u0117s teigimu, platforma yra modulin\u0117, tod\u0117l laikui b\u0117gant j\u0105 b\u016bt\u0173 galima taikyti ir kitoms neurodegeneracin\u0117ms ligoms.<\/p>\n
\u012emon\u0117s vadovas Jimas Scibetta sak\u0117, kad neurodegeneracin\u0117s ligos i\u0161lieka vieni sud\u0117tingiausi\u0173 medicinos i\u0161\u0161\u016bki\u0173, o pacientams ir j\u0173 \u0161eimoms skubiai reikia nauj\u0173 gydymo galimybi\u0173. Jo teigimu, finansavimas atspindi pasitik\u0117jim\u0105 komanda, platforma ir kuriam\u0173 program\u0173 potencialu.<\/p>\n
Did\u017eioji dalis pritraukt\u0173 l\u0117\u0161\u0173 bus skirta pagrindinei bendrov\u0117s programai VTx-002 vystyti, j\u0105 toliau vertinant vykstan\u010diame PIONEER-ALS 1\/2 faz\u0117s klinikiniame tyrime.<\/p>\n
Atviras, daugiacentris, tarptautinis tyrimas vertina tiriamosios terapijos poveik\u012f ALS sergantiems suaugusiesiems klinikin\u0117se vietose JAV, Europoje ir Jungtin\u0117je Karalyst\u0117je.<\/p>\n
Bendrov\u0117 skelbia, kad 2026 met\u0173 rugs\u0117j\u012f tyrimas buvo i\u0161pl\u0117stas nuo 12 iki 36 dalyvi\u0173, siekiant platesnio terapijos \u012fvertinimo. \u012emon\u0117 taip pat nurodo, kad finansavimas pad\u0117s jud\u0117ti \u012f priek\u012f ir kitoms programoms, ypa\u010d VTx-003, kuri kuriama Huntingtono ligai.<\/p>\n
Nors artimiausiu metu akcentuojami pagrindiniai projektai, \u201eVectorY Therapeutics\u201c deklaruoja siek\u012f augti kaip platformos principu paremtai biotechnologij\u0173 bendrovei, galin\u010diai nuosekliai spr\u0119sti keli\u0173 sunki\u0173 neurodegeneracini\u0173 b\u016bkli\u0173 biologinius mechanizmus.<\/p>\n","protected":false},"excerpt":{"rendered":"
Amsterdamo \u201eVectorY Therapeutics\u201c pritrauk\u0117 74,5 mln. eur\u0173, kad paspartint\u0173 ALS program\u0105 VTx-002 ir pl\u0117st\u0173 kitus neurodegeneracini\u0173 lig\u0173 projektus.<\/p>\n","protected":false},"author":0,"featured_media":70381,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[94],"tags":[9906,9722,2723,38361,9908,1040,55904],"miestas":[],"class_list":["post-70380","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finansai","tag-als","tag-amiotrofine-lateraline-skleroze","tag-europos-investiciju-bankas","tag-invest-nl","tag-neurodegeneracines-ligos","tag-startuoliai","tag-vectory-therapeutics"],"acf":[],"_links":{"self":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/70380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/comments?post=70380"}],"version-history":[{"count":0,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/posts\/70380\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media\/70381"}],"wp:attachment":[{"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/media?parent=70380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/categories?post=70380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/tags?post=70380"},{"taxonomy":"miestas","embeddable":true,"href":"https:\/\/cp.snarskis.lt\/index.php\/wp-json\/wp\/v2\/miestas?post=70380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}